Last reviewed 2026-05-26 · How we verify

SECOBARBITAL SODIUM

FDA-approved withdrawn Small molecule ✓ Verified May 2026 Quality 0/100

SECOBARBITAL SODIUM is a drug. It is currently FDA-approved (first approved 1950).

SECOBARBITAL SODIUM is a small molecule that acts as a positive allosteric modulator of the GABA-A receptor, an anion channel. It has been studied in a Phase I clinical trial at Johns Hopkins University as part of an investigation into the effects of hallucinogens and other drugs on mood and performance in healthy individuals.

At a glance

Generic name	SECOBARBITAL SODIUM
Modality	Small molecule
Phase	FDA-approved
First approval	1950

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Effects of Hallucinogens and Other Drugs on Mood and Performance (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SECOBARBITAL SODIUM CI brief — competitive landscape report
SECOBARBITAL SODIUM updates RSS · CI watch RSS

Frequently asked questions about SECOBARBITAL SODIUM

What is SECOBARBITAL SODIUM?

SECOBARBITAL SODIUM is a Small molecule drug.

When was SECOBARBITAL SODIUM approved?

SECOBARBITAL SODIUM was first approved on 1950.

What development phase is SECOBARBITAL SODIUM in?

SECOBARBITAL SODIUM is FDA-approved (marketed).

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing